ETNB - NASDAQ

89bio, Inc.

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%
HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.20B
EPS-3.5100
P/E Ratio-2.23
Earnings Date11/06/2025

etnb

Net Cash Provided by Financing Activities

Last Annual Value

218.59M

3-Year CAGR

109%

5-Year CAGR

15%

10-Year CAGR

25%

89bio, Inc.

89bio, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

ETNB · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
ETNB logo
89bio, Inc.
NASDAQ:ETNB
218.59M
-24.8%55.7%N/A 
AGIO logo
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
8.68M
16.9%N/A-25.7%
BEAM logo
Beam Therapeutics Inc.
NASDAQ:BEAM
478.05M
20.0%-8.8%N/A
COGT logo
Cogent Biosciences, Inc.
NASDAQ:COGT
878.23M
75.1%87.4%N/A
DNLI logo
Denali Therapeutics Inc.
NASDAQ:DNLI
189.22M
119.8%57.8%-4.5%
IBRX logo
ImmunityBio, Inc.
NASDAQ:IBRX
400.24M
-10.5%-4.6%N/A
LQDA logo
Liquidia Corporation
NASDAQ:LQDA
59.73M
11.4%17.8%25.6%
OCUL logo
Ocular Therapeutix, Inc.
NASDAQ:OCUL
561.72M
49.0%187.7%98.7%
RCUS logo
Arcus Biosciences, Inc.
NYSE:RCUS
488.00M
145.5%15.5%21.4%
RXRX logo
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
521.53M
55.0%2.6%N/A
89bio, Inc.

89bio, Inc. Fair Value Envelope

ETNB · NASDAQ

Our analysis suggests that ETNB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.84, this represents a potential HIDDEN relative to our calculated worth for 89bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $14.84

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.